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Abstract
Background: Alternative splicing is an important gene regulation mechanism. It is estimated that
about 74% of multi-exon human genes have alternative splicing. High throughput tandem (MS/MS)
mass spectrometry provides valuable information for rapidly identifying potentially novel
alternatively-spliced protein products from experimental datasets. However, the ability to identify
alternative splicing events through tandem mass spectrometry depends on the database against
which the spectra are searched.
Results: We wrote scripts in perl, Bioperl, mysql and Ensembl API and built a theoretical exon-
exon junction protein database to account for all possible combinations of exons for a gene while
keeping the frame of translation (i.e., keeping only in-phase exon-exon combinations) from the
Ensembl Core Database. Using our liver cancer MS/MS dataset, we identified a total of 488 non-
redundant peptides that represent putative exon skipping events.
Conclusion: Our exon-exon junction database provides the scientific community with an efficient
means to identify novel alternatively spliced (exon skipping) protein isoforms using mass
spectrometry data. This database will be useful in annotating genome structures using rapidly
accumulating proteomics data.
Background
Alternative splicing in eukaryotes is a process that enables
a single gene locus to encode for multiple protein prod-
ucts. Johnson et al. used exon-junction arrays to profile
more than 10,000 multi-exon human genes in 52 tissues
and cell lines and they estimated that about 74% of multi-
exon human genes are alternatively spliced [1]. Recently,
Pan et al. and Wang et al. used mRNA-Seq (mRNA
sequencing using the next-generation sequencing) tech-
nology and estimated that transcripts from about 92–95%
of multiexon genes undergo alternative splicing [2,3].
Alternative splicing events were traditionally identified by
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aligning cDNAs to genomic sequences. With the vast
number of Expressed Sequence Tags (EST) generated by
the EST sequencing projects [4], and more recent develop-
ment in direct mRNA sequencing (mRNA-Seq) by the next
generation sequencing technologies, many alternative
splicing events of genes were identified and annotated in
the human genome.
With the advances in mass spectrometry (MS) and large-
scale generation of MS/MS (tandem MS)-based proteom-
ics data, it has become clear that MS-based peptide
sequence data can be mined to identify and validate alter-
native splicing events of genes. Traditionally, mass spec-
trometry database searches use databases consisting of
known or putatively translated protein sequences, which
are biased towards well-known proteins or their common
alternatively spliced isoforms that exist in the database.
More recently, several methods have been proposed to
search for identifying novel alternative splicing variants.
Edwards [5] proposed a method using ESTs and a
sequence database compression strategy to identify alter-
natively-spliced peptides existing in the EST database
from MS data. However, as most EST sequences were only
sequenced once and they contained large number of
errors, using the ESTs to search against the mass spectrum
data, which is also imperfect, often generate low confi-
dence matches, and it is hard to distinguish bad EST
sequences from bad or mis-ionized mass spectra. Alterna-
tively, six-frame translated human genome sequences can
be used to search MS spectrum data directly [6,7]. Fermin
et al. were able to identify 282 novel open reading frames
with a false discovery rate threshold of 0.05 from the puta-
tive six-frame translation of the human genome [7]. How-
ever, the six-frame translation approach [6,7] does not
take into account all potential splicing possibilities.
We therefore sought to develop a new strategy to build a
database for more efficient identification of novel alterna-
tive splicing events using MS data. We designed a theoret-
ical exon-exon junction protein database to account for all
possible combination of exons for a gene while keeping
the frame of translation (i.e., keeping only in-phase exon-
exon combinations). Our database was built from the
Ensembl Core Database using scripts we wrote in perl,
Bioperl, mysql and Ensembl API. It contains every com-
patible exon-exon junction protein sequence encoded in
the human genome. Using liver cancer MS/MS data we
generated in the laboratory as an example, we show that
our database is useful in identifying from MS/MS spectra
novel alternatively spliced protein isoforms derived from
exon skipping.
Results
Construction of an exon-exon junction database
We built a putative exon-exon junction translation pro-
tein database representing all compatible exon-exon junc-
tion sequences using the Ensembl Core Database
(homo_sapiens_core_45_36h) from http://www.ense
mbl.org. We took 25 amino acid residues for each exon
from those compatible exon combinations or the whole
exon if an exon codes for less than 25 amino acids. The
reason for doing so is described below. A typical ion-trap
mass spectrometer has a window size to detect peptides
with molecular weight from 500 to 3000 daltons. A pep-
tide with 25 amino acids would have a molecular weight
of about 3000 daltons, which is at the upper range of MS
detection. The total number of genes in the database was
15, 536; the total number of exons was 203,180. The aver-
age junction sequence per gene is 56. We then excluded
282,991 previously described exon-exon junction
sequences if they have been annotated in the Ensembl
database, since our purpose is to identify novel splicing
isoforms. This reduction in the size of the exon-exon junc-
tion database saves MS search time. The final database has
873,024 entries and is about 132 Mb in size.
This program was implemented in Perl. The database and
source code can be downloaded from our website at http:/
/www.zcni.zju.edu.cn/en/db_peej.htm.
Identification of exon skipping events from mass 
spectrometry data using the exon-exon junction database
To test the ability of our exon-exon junction database in
identifying new splicing events, and to test the hypothesis
that novel splicing events could be captured by mass spec-
trometry as peptides spanning new exon junctions, we
performed mass spectrum searches against the putative
exon-exon junction database with a liver MS dataset we
generated in the laboratory [8]. The dataset contains 321
mzXML files with a total of 1, 327,430 mass spectra, of
which 14,583 spectra have PeptideProphet scores > 0.9.
We first used the open source search engine X!Tandem to
search against our AS database to identify candidate AS
forms. From the 321 mzXML files from liver cancer sam-
ples, we found 1063 novel exon skipping peptides, of
which 421 peptides (39.6%) were uniquely identified as
non-redundant. We searched against a sequence-rand-
omized version of the putative exon-exon junction data-
base as a decoy database using X!Tandem; the FDR is
0.98%.
By combining multiple search engines for proteomics, it is
possible to improve the sensitivity in identification of
peptides from MS/MS data without sacrificing accuracy as
demonstrated by Balgley et al. [9]. To increase our chance
in identifying alternatively spliced isoforms, we per-
formed additional searches using SEQUEST [10], keeping
the same pipeline and the same search parameters as with
the X!Tandem search. We identified 238 novel exon skip-
ping peptides, of which 79 peptides (33.2%) were
uniquely identified as non-redundant. By searchingBMC Bioinformatics 2008, 9:537 http://www.biomedcentral.com/1471-2105/9/537
Page 3 of 8
(page number not for citation purposes)
against the same decoy database as described above, the
FDR of the SEQUEST result is 4.99%.
Combining these two searches, we identified a total of
488 non-redundant peptides that represent putative novel
splicing events (Additional file 1). Among them, 408 were
identified only by X!tandem, 66 were identified only by
SEQUEST and 13 were identified by both methods. This is
similar to what Balgley et al. found that the number of
proteins with two or more distinct peptides identified by
X!Tandem is about 5 times that identified by SEQUEST
[9]. Many putative alternatively spliced peptides were
identified multiple times and are listed multiple times in
the Additional file 1. These 488 peptides were derived
from 395 Ensembl genes as some genes have multiple
alternatively spliced peptides.
Figure 1 (top panel) shows the spectrum of a novel junc-
tion peptide LDEEVKIQR, which was not previously iden-
tified in either the ECgene or the human non-redundant
database. This peptide was observed in both liver cancer
and normal datasets. The peptide matched to gene
ENSG00000143375, which encodes cingulin. The cingu-
lin gene has 28 exons and is transcribed into a 5142 nucle-
otide mRNA (NM_020770). The b6 ion for LDEEVK and
the b7 ion for LDEEVKI are clearly identified (Figure 1,
top panel). The junction position is between amino acid
K and I (LDEEVK/IQR, where "/" stands for junction posi-
tion). It is derived from joining ENSE00000959672 (exon
6) and ENSE00000959682 (exon 21) of the cingulin
gene. Cingulin is a protein with modular coiled coil
domain, is localized in tight junctions, and may play a
role in regulating paracellular permeability [11,12]. The
significance and function of this spliced isoform remains
to be investigated. The bottom panel of figure 1 shows the
spectrum of the peptide KAFGENYLFPDGR. This peptide
is derived from splicing of exon ENSE00001240795 (exon
3) and ENSE00001128289 (exon 7) of
ENSG00000110395, which encodes for the proto-onco-
gene c-CBL (E3 ubiquitin-protein ligase CBL). Figure 2
illustrates the splicing event involving exon 3 and 7 of the
gene. In our analysis, about 40% of the exon skipping
events skipped 7 exons and about 25% of them skipped
14 exons (Additional file 2). Our two examples skip 4 and
15 exons respectively and are typical of the observed skips.
Discussion
We constructed a putative exon-exon junction database
and demonstrated that our database could facilitate the
identification of novel alternative splicing variants using
high throughput proteomics experimental data. Our
approach adds to the methods of identifying alternative
splicing forms and is unique. Fermin et al proposed to use
the non-redundant database derived from the ECgene
database to search for novel putative alternative splicing
variants (Fermin D., personal communication). The
ECgene database provides annotation for gene structure,
function and expression [13]. The ECgene database takes
alternative splicing into consideration and is a good start-
ing point for the identification of putative alternatively
spliced transcripts. Search against the six-frame transla-
tion of the human genome is another approach [6,7]. But
the database is more than 300 times the size of the com-
monly used IPI human protein sequence database, which
requires extensive search time as mass spectrum search
engines typically require running time linear with size of
the sequence database used for searches [5]. In addition,
six-frame translation of the human genome did not take
into account alternatively spliced exons.
With this exon-exon junction approach, we identified a
substantial number of novel alternative splicing junction
sequences that were not defined in the public databases,
including the comprehensive ECgene database dedicated
to identifying human alternative splicing events http://
genome.ewha.ac.kr/ECgene/ and the human non-redun-
dant database (NCBI-nr). We tested our approach using
14,583 spectra from liver cancer cell secretome that have
PeptideProphet scores > 0.9. Our MS data is not represent-
ative of the whole proteome and the statistics derived
from this analysis regarding number of alternative splic-
ing events should not be extrapolated to whole proteome
or to other tissues. We merely used this dataset to illustrate
the methodology and the idea that mass spectrum data
can be used to identify alternatively spliced protein iso-
forms.
Our liver secretome MS/MS data account for 1, 528 pro-
teins [8]. From these, we identified a total of 488 non-
redundant peptides that represent putative novel splicing
events (Additional file 1). These 488 peptides are derived
from 395 Ensembl genes as some genes have multiple
alternatively spliced peptides. The average number of
putative splicing events per protein is therefore estimated
at 0.32 (488/1528). This is similar to the frequency of
0.33 splice variant per protein from another observation
by us, in which we identified 420 splice variant from 1278
proteins from a large dataset of mass spectra derived from
plasma proteome of a mouse model of human pancreatic
ductal adenocarcinoma [14]. In addition, we compiled a
known exon-exon junction database from ECgene and
NCBI's non-redundant databases and used it to search the
same liver secretome MS/MS data. We identified a total of
1521 known exon-exon junctions based on the same cri-
teria we used to identify novel exon-exon junctions (data
not shown). These 1521 known exon-exon junction
derived from 1483 genes (1.03 exon-exon junction per
gene), which is in contrast with 488 peptides that we iden-
tified from 395 Ensembl genes (1.24 exon-exon junction
per gene) when we used the novel combinational exon-BMC Bioinformatics 2008, 9:537 http://www.biomedcentral.com/1471-2105/9/537
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Top panel, the mass spectrum for the peptide LDEEVKIQR; bottom panel, the mass spectrum for the peptide KAFGENYLFP- DGR Figure 1
Top panel, the mass spectrum for the peptide LDEEVKIQR; bottom panel, the mass spectrum for the peptide 
KAFGENYLFPDGR. Matched b-ions (e.g. b2+, b6+) are indicated by red, and matched y-ions (e.g. y7+) are indicated by 
blue. The + indicates that an ion is a singly-charged ion.BMC Bioinformatics 2008, 9:537 http://www.biomedcentral.com/1471-2105/9/537
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exon junction database we built. This suggests that there
are many novel exon-exon alternative splicing forms that
were not captured in the current ECgene or NCBI's nr
database.
Utility
The exon-exon junction database is useful in finding alter-
native splicing events from high throughput proteomics
data generated from modern mass spectrometers. One can
simply use this AS junction database instead of the regular
protein database in MS database searches, while keeping
the search engine and the search parameters the same as
searching regular protein databases. The output is a list of
hits. One can further process this list using statistics devel-
oped for processing MS search results, such as Peptide-
Prophet, to retain only highly confident hits.
The caveat is that our database is based on annotations
from ENSEMBL (homo_sapiens_core_45_36h). Our
approach is limited to identifying novel splicing forms
derived from combinations of known exons. It will not
allow the identification of splicing involved in unidenti-
fied or un-annotated exons or genes in the human
genome. When new ENSEMBL build and new annota-
tions (e.g. new exons) are available, the database should
be updated to include new information. We will provide
such an updated database when there is a significant new
build of the ENSEMBL database.
Availability
The database can be downloaded from our website at
http://www.zcni.zju.edu.cn/en/db_peej.htm.
Methods
Construction of putative Exon-Exon junction translation 
protein database
Ensembl Core Database (homo_sapiens_core_45_36h)
was downloaded from the Ensembl website http://
www.ensembl.org into a local MySQL database. We built
the putative exon-exon junction translation protein data-
base, taking 25 amino acids from the end of an exon and
25 amino acids from the beginning of the next exon.
However, as not all exon-exon combinations from a given
gene are compatible, we need to consider combinations of
exons that are in-phase. A phase indicates the position
within a codon where an exon ends or starts. Phase 0 indi-
cates that an exon ends and starts between two codons;
phase 1 indicates that an exon ends and starts between the
first and second base of a codon; and phase 2 indicates
that an exon ends and starts between the second and third
bases of a codon (Additional file 3). Phase -1 (minus 1)
indicates that the exon is a non-coding exon (e.g., 5' UTR).
We only included combinations of exons that are in
Illustration of splicing of exons 3 and 7 of the proto-oncogene c-CBL that generates the peptide KAFGENYLFPDGR we identi- fied by MS/MS Figure 2
Illustration of splicing of exons 3 and 7 of the proto-oncogene c-CBL that generates the peptide KAFGE-
NYLFPDGR we identified by MS/MS. Translated amino acid residues (one letter code) were aligned with the combined 
exon 3 and 7 DNA sequences. The double forward-slash indicates the exon/exon junction. The underlined amino acid residues 
indicate the peptide corresponding to the mass spectrum we identified.BMC Bioinformatics 2008, 9:537 http://www.biomedcentral.com/1471-2105/9/537
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Flowchart of our pipeline for identifying exon skipping forms using MS/MS data Figure 3
Flowchart of our pipeline for identifying exon skipping forms using MS/MS data.BMC Bioinformatics 2008, 9:537 http://www.biomedcentral.com/1471-2105/9/537
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phase, which means that the end phase of the first exon
must match in frame with the start phase of the next exon,
thereby not creating any frame-shift after translation.
SEQUEST or X!Tandem searches
We used two liver mass spectrometry datasets to perform
X!Tandem and SEQUEST searches against the constructed
putative exon-exon junction protein database. The two
datasets (one is cancer, the other is normal) were gener-
ated using multiple dimension liquid chromatography
(MDLC) coupled to a LTQ-Orbitrap (Thermo Scientific
Inc.) mass spectrometer. We converted all RAW mass spec-
tra to mzXML files (160 for liver cancer tissues and 161 for
normal adjacent tissues) by ReAdw http://sashimi.source
force.net/, then analyzed them using the X!Tandem open
source protein identification program [15] or the Tur-
boSEQUEST (Bioworks version 3.2, Termo Electron)[16]
(Figure 3). Searching parameters for X!Tandem and
SEQUEST were set the same. Searches were performed
using a fragment monoisotopic mass error tolerance of
400 ppm and parent monoisotopic mass tolerance of +/-
10 ppm. In the search parameters, we included one static
post-translational modification for cysteine (+57.022 dal-
tons) and four optional post-translational modifications
(+16 for methionine and + 80 daltons for serine, threo-
nine and tyrosine). Trypsin was used as proteolytic cleav-
age enzyme, and one missed cleavage site was allowed.
For the X!Tandem search results, the filtering criterion was
set at an expect value <= 0.02. For the results from the
SEQUEST search algorithm, the filtering criteria for
accepting a peptide were set at dCN > 0.1 and X-correla-
tion scores for charge +1, +2, and +3 ions greater than 1.5,
2.0, 2.5, respectively [17] (see Figure 3). We defined a can-
didate junction peptide as one striding over two exons
where there are >= 2 amino acids in each exon matched to
a spectrum.
All searches were performed in a Linux cluster based on an
MPI (Massive Passing Interface) environment [18]. In
order to calculate the false discovery rate (FDR) of the
X!Tandem/SEQUEST results, a sequence-randomized ver-
sion of the putative exon-exon junction database was used
as a decoy database to combine with the original database
and searched using the same parameters for X!Tandem/
SEQUEST. This randomized database was built by replac-
ing each real database entry with a random sequence of
the same length but with the average AA composition for
the entire database. The perl script used to randomize the
database entries was downloaded from http://
www.matrixscience.com/downloads/decoy.pl.gz. We
chose the random option of the perl script (i.e. decoy.pl [-
-random] input.fasta [output.fasta]), for which the output
entries are random sequences with the same average
amino acid composition as the input database. The false
discovery rate (FDR) was calculated by Ndecoy/Ncom-
bined, where Ndecoy (namely FP, false positives) is
number of matches to the entries from decoy database
and Ncombine (namely FP+TP, false positives + true pos-
itives) is number of matches to the combined database.
The FDR controls the expected proportion of false posi-
tives under certain threshold for large-scale proteomics
data searches [19-21].
Selection of high-confidence putative exon-exon junction 
peptides
We wrote perl scripts to parse XML output files of X!Tan-
dem analysis and EXCEL output files of SEQUEST analy-
sis. These output spectra were subdivided into 2 classes:
(a) spectra that only match to one exon; (b) spectra that
cover junction sequences (striding over two exons where
there are >= 2 amino acids in each exon) of two exons. All
candidate peptides which belong to class b were aggre-
gated into a FASTA format file for further BLAST analysis.
Removing known splicing forms by searching against the 
human non-redundant database
Candidate exon-exon junction peptides were searched
against both the ECgene non-redundant database [22]
and Human non-redundant database ftp://
ftp.ncbi.nih.gov/blast/db/FASTA/nr.gz, using BLASTP and
the PAM30 matrix [7,23] while turning off the gapped
alignment. Only those peptides that have less than 95%
identity to or that have no hit in the ECgene non-redun-
dant database or the NCBI non-redundant (nr) database
were considered to be novel alternative splicing variants.
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